Nutriband Inc. (NASDAQ: NTRB) was highlighted in a recent Channelchek report by Noble Capital Markets, summarizing the company's presentation at Noble's Virtual Emerging Growth Conference. The report, dated Oct. 23, 2025, focuses on Nutriband's lead product, AVERSA Fentanyl, an abuse-deterrent transdermal patch designed to release aversive agents if tampered with, thereby reducing the risk of opioid misuse. The announcement underscores the potential significance of this technology in addressing the opioid crisis, with market projections estimating annual sales of $200 million, potentially rising to $800 million if the FDA mandates abuse-deterrent patches across the entire category.
Nutriband has completed its manufacturing scale-up with Kindeva Drug Delivery, a key step toward commercialization. The company expects to begin a human abuse liability study in early 2026 and file a New Drug Application later that year. These milestones are critical for advancing AVERSA Fentanyl toward regulatory approval and market entry. The report notes that Noble Capital Markets has reaffirmed its Outperform rating and $15 price target for Nutriband, citing the company's ability to fund research and development through its contract manufacturing division without diluting shareholder value.
The implications of this announcement are multifaceted. If the FDA mandates abuse-deterrent formulations for all transdermal fentanyl products, Nutriband's AVERSA technology could become a standard requirement, opening a substantial market opportunity. Even without a mandate, the product addresses a pressing public health need by deterring abuse, misuse, diversion, and accidental exposure. The successful development and adoption of AVERSA Fentanyl could position Nutriband as a leader in abuse-deterrent transdermal drug delivery.
For investors, the news provides clarity on Nutriband's strategic progress and financial outlook. The company's dual revenue model—generating income from its contract manufacturing division while advancing its proprietary pipeline—offers a balanced approach to funding growth without relying heavily on external capital. The reaffirmed price target from Noble Capital Markets adds credibility to the company's valuation and future prospects.
To view the full report from Channelchek, visit https://ibn.fm/bClpc. Additional updates on Nutriband are available in the company's newsroom at https://ibn.fm/NTRB.
